Fig 1: CCL5 emerges as an upstream regulator of PBMC activation upon plasma stimulation.a, Ingenuity Pathway Analysis performed using the DEGs in PBMCs from healthy donors stimulated with either atherosclerotic plasma (n = 20 biologically independent samples, 10 men) or plasma from healthy donors (n = 12 biologically independent samples) revealed the top upstream regulators. Upstream regulators were plotted using the activation z-score from Ingenuity Pathway Analysis. Fisher’s exact test was used; P < 0.05 was considered statistically significant. b, Differentially expressed cytokines in plasma from patients with atherosclerosis (n = 20 biologically independent samples, 10 men) versus healthy donors (n = 15 biologically independent samples). Dots represent plasma levels of the tested cytokines and are expressed as picograms per milliliter. Dotted line represents the average (Ave.). P values were calculated by two-tailed unpaired t-test; P < 0.05 was considered statistically significant. c, Heat map of phosphoprotein expression in both monocytes and CD1c+ DCs in PBMCs from healthy donors stimulated with healthy plasma alone (healthy) or in combination with CCL5 (10,000 pg µl−1), CXCL1 (600 pg µl−1), CXCL10 (200 pg µl−1), PDGF-AA (600 pg µl−1) and PDGF-BB (500 pg µl−1). z-Scores were used to identify the significant changes in phosphorylation levels (n = 3 biologically independent samples per condition). d, viSNE plot of all major PBMC cell types defined based on canonical expression patterns. e, Intracellular signaling patterns were visualized across this immune map in response to plasma from patients with atherosclerosis admixed with either an antihuman CCL5 antibody (0.16 µg µl−1; n = 6 biologically independent samples, 3 men) or isotype control antibody (0.16 µg µl−1; n = 6 biologically independent samples, 3 men). Unstimulated PBMCs were included as control (no plasma). f, Dot plots show the effect of CCL5 blocking on the phosphorylation of intracellular kinases in CD14+ monocytes and CD1c+ DCs after stimulation with atherosclerotic plasma. P values were determined by unpaired two-tailed t-test.
Fig 2: Schematic illustration of chemokine mechanisms of interaction between bladder cancer (BC) cells and macrophage.A. Macrophages polarize into M2-like tumor-associated macrophages (TAMs) via interaction with BCs, and CXCL1 secretion from BC cells contributes to their polarization.B. CXCL1 also contributes to the activation of BC cell migration and invasion through an autocrine effect.C. CCL20 induces BC cells to increase MEK/ERK phosphorylation and expression of epithelial–mesenchymal transition (EMT) markers, activating BC cell migration and invasion.D. Interaction with TAMs increases CCR6 expression in BC cells, enhancing their sensitivity to tumor-associated macrophage (TAM)-derived CCL20.E. BC cells activated by CCL20 secretion from TAMs have enhanced metastatic potential.
Fig 3: Circulating levels of candidate cytokines correlated with phospho-sites activated in monocytes.A. Spearman correlation of CCL5 levels in plasma of atherosclerotic patients with intracellular signal intensity of pCREB, pp38, pERK1/2, pMAPKAPK2 and pS6 phosphorylation in monocytes. B. Spearman correlation of CXCL1 levels in plasma of atherosclerotic patients with intracellular signal intensity of pCREB, pp38, pERK1/2, pMAPKAPK2 and pS6 phosphorylation in monocytes. C. Spearman correlation of CXCL10 levels in plasma of atherosclerotic patients with intracellular signal intensity of pCREB, pp38, pERK1/2, pMAPKAPK2 and pS6 phosphorylation in monocytes. D. Spearman correlation of PDGFAA levels in plasma of atherosclerotic patients with intracellular signal intensity of pCREB, pp38, pERK1/2, pMAPKAPK2 and pS6 phosphorylation in monocytes. E. Spearman correlation of PDGFBB levels in plasma of atherosclerotic patients with intracellular signal intensity of pCREB, pp38, pERK1/2, pMAPKAPK2 and pS6 phosphorylation in monocytes. P < 0.05 was considered significant. Data are from n = 20; biologically independent samples; males=10. Data are presented as mean and error with 95% CI.
Fig 4: The effect of CXCL1 on bladder cancer (BC) cells.A. ELISA analysis of CXCL1. There was no significant difference in CXCL1 concentration between conditioned media (CM) from BC cells alone and CM from ST3 generation.B. RT-qPCR analysis of CXCL1. CXCL1 mRNA expression was significantly upregulated in BC cells, indicating that CXCL1 is mainly secreted by BC cells.C. Treatment of ST1 with rhCXCL1 decreased CD68 expression and increased CD206 expression in a concentration-dependent manner.D ELISA analysis of CCL20. Treatment with rhCXCL1 enhanced CCL20 secretion from ST1 cells.E. Migration assay of BC cells. Migration was enhanced by rhCXCL1 in a concentration-dependent manner.F. Invasion assay of BC cells. Invasion was enhanced by rhCXCL1 in a concentration-dependent manner.G. Western blot (WB) analysis showed that rhCXCL1 treatment increased MEK/ERK phosphorylation and expression levels of epithelial–mesenchymal transition (EMT) markers.H. Migration assay of BC cells. ST1 cells treated with CXCL1 showed significantly enhanced migration compared to untreated ST1 cells.I. Invasion assay of BC cells. ST1 cells treated with CXCL1 showed significantly enhanced invasion compared to untreated ST1 cells.J. Coculture with ST1 cells treated with CXCL1 further enhanced MEK/ERK phosphorylation and the expression of epithelial–mesenchymal transition (EMT) markers.K. CCL20 administration significantly enhanced BC cell migration more than CXCL1 administration. The combined administration of CXCL1 and CCL20 did not result in significantly different migration enhancement compared to CCL20 alone.
Supplier Page from BioLegend for Recombinant Human CXCL1 (GRO-α) (carrier-free)